Overview

CDVAX is a project funded under the European Union 7th Framework Programme. The aim of CDVAX is to take forward a novel and highly innovative oral vaccine that will provide protection against Clostridium difficile infection. This novel approach will use the spores of a genetically engineered harmless bacteria to generate a vaccine to protect vulnerable patients against this serious and life threatening hospital acquired infection. This project will develop the vaccine and evaluate it in a human clinical trial.

To learn more about Clostridium difficile and the illness it causes click here.

Project title

Oral Vaccination against Clostridium difficile Infection.

Work Programme

HEALTH.2013.2.3.1-1
“Drugs and vaccines for infections that have developed or are at risk of developing significant anti-microbial resistance”.

Project Coordinator

Professor Simon Cutting
School of Biological Sciences,
Royal Holloway University of London, UK
E-mail: s.cutting@rhul.ac.uk
Phone: +44-(0)1784 443760
Fax: +44 (0)1784 414224

Partners

The project is being implemented by a consortium of five partners, four of whom are Small-Medium Enterprises (SMEs). Further details can be found here. The consortium is supported by a Scientific Advisory Board.